Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL
January 16th 2024A brief discussion on evolving practice standards and clinical perspectives that help to inform selection of best therapy for patients with DLBCL that progress beyond initial therapy.
Read More
Dr. Falchi on the Use of Epcoritamab with R-CHOP Therapy in High-Risk DLBCL
June 4th 2022Lorenzo Falchi, MD, discusses the updated findings from the phase 1/2 EPCORE NHL-2 trial trial evaluating the subcutaneous administration of epcoritamab with R-CHOP in patients with high-risk diffuse large B-cell lymphoma.
Read More